We are delighted to inform you that on May 4, Ontario Health-Cancer Care Ontario (OH-CCO) announced an expansion into comprehensive cancer biomarker testing, at diagnosis, to support patient management.

Stage 1 will launch on June 1, 2021 and the following changes will take effect:

- This stage will affect biomarker testing for non-small cell lung cancer, uveal and cutaneous melanoma, colorectal and small bowel cancers.
- Most cases will now have Next Generation Sequencing (NGS) for multiple genes done as the first test. Former single variant or single gene tests will no longer be used, as the NGS panel now includes these genes and variants.
- Please see the attached list outlining the detailed changes to the biomarker testing.
- The updated requisition form will be available here on June 1.

Expanded biomarker testing for other tumor sites is anticipated from OH-CCO in August and September, and we will keep you informed to test changes at that time. In some cases, genes beyond those minimally funded by CCO have been included based on current and emerging clinical needs and targeted therapies.

For questions regarding operations and logistics, please contact: Wes Morrison, Manager Clinical Laboratory Genetics at Wes.Morrison@uhn.ca or 416-340-4800 x 6698
For questions regarding the clinical implications of the biomarker testing, please contact: Dr. Tracy Stockley at Tracy.Stockley@uhn.ca

Kind regards,

Dr. Tracy Stockley
Head of Clinical Laboratory Genetics
Laboratory Medicine Program
University Health Network

Christine Bruce
Senior Director
Laboratory Medicine Program
University Health Network